Q2 2025 Penumbra Inc Earnings Call Transcript
Key Points
- Penumbra Inc (PEN) reported a strong revenue growth of 13.4% year-over-year, reaching $339.5 million in the second quarter of 2025.
- The US thrombectomy business led growth with a 22.6% increase in revenue, driven by the adoption of the CAVT portfolio.
- Gross margin improved to 66% from 54.4% in the previous year, excluding a one-time inventory write-off.
- The company successfully completed enrollment in the STORM-PE trial, which could provide significant clinical evidence for PE treatment.
- Penumbra Inc (PEN) increased its full-year revenue guidance to a range of $1.355 billion to $1.370 billion, indicating confidence in continued growth.
- International revenue decreased by 3.2%, primarily due to a decline in China, although other regions showed growth.
- Operating expenses increased due to investments in the commercial team, impacting operating margins.
- The gross margin slightly decreased sequentially due to the launch of the XL product and high international sales mix.
- There is uncertainty regarding the FDA review timeline for the Thunderbolt product, which could impact future growth.
- The neurovascular market showed softer growth, with Penumbra Inc (PEN) relying on share gains to drive performance.
Ladies and gentlemen, good afternoon. My name is Abby, and I'll be your conference operator today. At this time, I would like to welcome everyone to Penumbra's second-quarter 2025 conference call. (Operator Instructions)
Thank you. And I would like to introduce Ms. Cecilia Furlong, Business Development and Investor Relations for Penumbra. Ms. Furlong, you may begin your conference.
Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for the second quarter of 2025. A copy of the press release and financial tables, which includes a GAAP to non-GAAP reconciliation, can be viewed under the Investors tab on our company website at www.penumbrainc.com.
During the course of this conference call, the company will make forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
